JAZZ insider sale notice: 3,731 vested shares to be sold via ETRADE

Rhea-AI Filing Summary

Jazz Pharmaceuticals (JAZZ) submitted a Form 144 reporting a proposed sale of 3,731 shares of common stock through ETRADE Financial Corporation on 08/08/2025 with an aggregate market value of $417,872. The filing shows the shares were acquired on 08/07/2025 through restricted stock vesting and were granted as compensation. The form states there were no securities sold in the past three months by the selling person and includes the seller's certification that they are not aware of undisclosed material adverse information about the issuer. The shares represent a very small fraction of the 60,658,809 shares outstanding.

Insights

Securities Analyst

TL;DR: Routine insider sale from recent restricted stock vesting; size is immaterial to company capitalization.

The filing documents a proposed sale of 3,731 shares acquired through restricted stock vesting and classified as compensation, to be executed through ETRADE Financial Corporation on 08/08/2025, at an aggregate value of $417,872. Given the 60,658,809 shares outstanding, the position is negligible relative to total equity, suggesting limited market impact. The disclosure that there were no sales in the prior three months and the signer’s certification regarding undisclosed material information are standard Form 144 elements. This notice does not present new operational or financial information about the issuer.

Corporate Governance Expert

TL;DR: Filing reflects routine compensation-related vesting and planned sale; governance implications are standard and non-material.

The transaction is recorded as restricted stock vesting with payment characterized as compensation, indicating the shares stem from employee or executive equity awards rather than an open-market purchase. The use of a broker and the explicit representation about undisclosed material adverse information align with compliance expectations for insider dispositions. There are no disclosures here of unusual acceleration, related-party issues, or clustered prior sales that would raise governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	ETRADE FINANCIAL CORPORATION ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3731	417872.00	60658809	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/07/2025	RESTRICTED STOCK VESTING	ISSUER			3731	08/07/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Jazz Pharmaceuticals (JAZZ) report?

It reports a proposed sale of 3,731 common shares through ETRADE Financial Corporation on 08/08/2025 with an aggregate market value of $417,872.

How were the 3,731 JAZZ shares acquired?

The shares were acquired on 08/07/2025 via restricted stock vesting and the nature of payment is listed as compensation.

Does the filing show prior sales by the seller in the last three months?

No; the Form 144 states there were no securities sold during the past three months by the person for whose account the securities are to be sold.

Who is the broker handling the sale in the Form 144?

ETRADE Financial Corporation is identified as the broker for the proposed sale.

How large is the proposed sale relative to outstanding shares?

The filing lists 60,658,809 shares outstanding; the proposed sale of 3,731 shares represents a very small fraction of that total.